DWA
PVLA

Dorsey Wright & Associates’s Palvella Therapeutics PVLA Stock Holding History

Dorsey Wright & Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-104
Closed -$43K – 344
2021
Q3 		$43K Buy
+104
New +$36.2K 0.01% 250
2019
Q4 		– Sell
-27
Closed -$7K – 362
2019
Q3 		$7K Buy
+27
New +$10.5K ﹤0.01% 284

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dorsey Wright & Associates's PVLA Position: Q4 2021 in Review

Dorsey Wright & Associates sold out of Palvella Therapeutics (PVLA) in Q4 2021, closing a stake of 104 shares — an estimated $43K sold.

Dorsey Wright & Associates first reported a position in PVLA in Q3 2019 and held it in 2 quarters. The position peaked at $43K in Q3 2021. 81 funds tracked by Wall St. Rank hold PVLA as of Q4 2021.

  • Dorsey Wright & Associates reported no remaining Palvella Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 104 Palvella Therapeutics shares in Q4 2021, an estimated $43K.
  • Dorsey Wright & Associates first reported a position in Palvella Therapeutics in Q3 2019 and held it in 2 quarters.
  • Dorsey Wright & Associates's Palvella Therapeutics position peaked at $43K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2021.

Based on Dorsey Wright & Associates's 13F filing for Q4 2021, filed 27 Jan 2022.